For reprint requests, contact us at

Stuurman AL, Bollaerts K, Alexandridou M, Biccler J, Díez Domingo J, Nohynek H, et al.
Vaccine effectiveness against laboratory-confirmed influenza in Europe – Results from the DRIVE network during season 2018/19.
Vaccine. 2020. doi = 10.1016/j.vaccine.2020.07.063

Hall GC, Lanes S, Bollaerts K, Zhou X, Ferreira G, Gini R.
Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence.
Pharmacoepidemiology and drug safety. 2020. doi = 10.1002/pds.5109

Bonten M, Verstraeten T, Gravenstein S, Poolman J.
Reply to Baird and Douglas.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020. doi = 10.1093/cid/ciaa1106

Baay M, Neels P.
SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues.
Biologicals : journal of the International Association of Biological Standardization. 2020. doi = 10.1016/j.biologicals.2020.08.006

Arlegui H, Bollaerts K, Salvo F, Bauchau V, Nachbaur G, Bégaud B, et al.
Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.
Drug safety. 2020. doi = 10.1007/s40264-020-00984-7

Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, Bégaud B, Praet N.Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).
Drug safety. 2020. doi = 10.1007/s40264-020-00982-9

Baay M, Lina B, Fontanet A, Marchant A, Saville M, Sabot P, et al.
SARS-CoV-2: Virology, epidemiology, immunology and vaccine development.
Biologicals : journal of the International Association of Biological Standardization. 2020;66:35-40. doi = 10.1016/j.biologicals.2020.06.005

Khan AS, Blümel J, Deforce D, Gruber MF, Jungbäck C, Knezevic I, et al.
Report of the second international conference on next generation sequencing for adventitious virus detection in biologics for humans and animals.
Biologicals : journal of the International Association of Biological Standardization. 2020. doi = 10.1016/j.biologicals.2020.06.002

Van Baarle D, Bollaerts K, Del Giudice G, Lockhart S, Luxemburger C, Postma MJ, et al.
Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project.
Vaccine. 2020;38(37):5896-904. doi = 10.1016/j.vaccine.2020.07.005

Vorsters A, Bosch FX, Bonanni P, Franco EL, Baay M, Simas C, et al.
Prevention and control of HPV infection and HPV-related cancers in Colombia – a meeting report.
BMC Proc. 2020;14(Suppl 9):8. doi = 10.1186/s12919-020-00192-2

Verstraeten T, Fletcher MA, Suaya JA, Jackson S, Hall-Murray CK, Scott DA, Schmöle-Thoma B, Isturiz RE, Gessner BD.
Diabetes mellitus as a vaccine-effect modifier: a review.
Expert Rev Vaccines. 2020 Jun 9:1-9. doi:10.1080/14760584.2020.1760098.

Pollard AJ, Sauerwein R, Baay M, Neels P; HCT3 speakers and session chairs, Balasingam S, Bejon P, Berthels N, Bull S, Catchpole A, Chi PC, Chilengi R, Cox R, Davies H, Durbin A, Emary K, Emerson C, Frenck R, Grimwade O, Hobbs M, Kang G, Kaye P, Le Doare K, Levine MM, McShane H, Oguti B, Openshaw P, Osowicki J, Parker M, Ploin D, Porter C, Roestenberg M, Selgelid MJ, Wildfire A.
Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report.
Biologicals. 2020 Jun 3. pii: S1045-1056(20)30044-0. doi:10.1016/j.biologicals.2020.04.004.

Bonten M, Johnson JR, van den Biggelaar AHJ, Georgalis L, Geurtsen J, de Palacios PI, Gravenstein S, Verstraeten T, Hermans P, Poolman JT.
Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review.
Clin Infect Dis. 2020 May 14. pii: ciaa210. doi:10.1093/cid/ciaa210.

Bekeredjian-Ding I, Van Molle W, Baay M, Neels P; PEI speakers and session chairs, Conrad C, van Diepen A, Fortune S, Goetz K, Gorringe A, Hoft D, Johnson RA, Kremsner P, Krut O, Levy Y, Metzger W, Oeppling V, Stibitz S, Talaat KR, Thomas S, Wildfire A, Yakubu BN.
Human challenge trial workshop: Focus on quality requirements for challenge agents, Langen, Germany, October 22, 2019.
Biologicals. 2020 May 4. pii: S1045-1056(20)30045-2. doi:10.1016/j.biologicals.2020.04.005.

Bollaerts K, Rekkas A, De Smedt T, Dodd C, Andrews N, Gini R.
Disease misclassification in electronic healthcare database studies: Deriving validity indices-A contribution from the ADVANCE project.
PLoS One. 2020 Apr 22;15(4):e0231333. doi: 10.1371/journal.pone.0231333.

Arora NK, Das MK, Poluru R, Kashyap NK, Mathew T, Mathai J, Aggarwal MK, Haldar P, Verstraeten T, Zuber PLF; INCLEN Vaccine Safety Study Group.
A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts.
Pediatr Infect Dis J. 2020 May;39(5):389-396. doi:10.1097/INF.0000000000002594.

Bollaerts K, de Smedt T, McGee C, Emborg HD, Villa M, Alexandridou M, et al.
ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.08.012

Bollaerts K, Ledent E, de Smedt T, Weibel D, Emborg HD, Danieli G, et al.
ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.09.034

Emborg HD, Kahlert J, Braeye T, Bauwens J, Bollaerts K, Danieli G, et al.
ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.07.039

Gini R, Dodd CN, Bollaerts K, Bartolini C, Roberto G, Huerta-Alvarez C, et al.
Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.07.045

Sturkenboom M, Bahri P, Chiucchiuini A, Grove Krause T, Hahne S, Khromava A, et al.
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.07.081

Tin Tin Htar M, de Ridder M, Braeye T, Correa A, McGee C, de Lusignan S, et al.
Advance system testing: Vaccine benefit studies using multi-country electronic health data – The example of pertussis vaccination.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.08.078

Weibel D, Dodd C, Mahaux O, Haguinet F, De Smedt T, Duarte-Salles T, et al.
ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination.
Vaccine. 2019. doi = 10.1016/j.vaccine.2019.06.040

Ferreira G, Stuurman AL, Horsmans Y, Cattaert T, Verstraeten T, Feng Y, et al.
Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom
Clinical Practice Research Datalink. Eur J Gastroenterol Hepatol. 2019. doi = 10.1097/meg.0000000000001537

Bollaerts K, Alexandridou M, Verstraeten T.
Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England.
Vaccine: X. 2019;1(11 April 2019):100007. doi =

Bollaerts K, Verstraeten T, Cohet C.
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression.
Vaccine. 2019;37(1):34-40. doi = 10.1016/j.vaccine.2018.11.049

Braeye T, Bauchau V, Sturkenboom M, Emborg HD, Garcia AL, Huerta C, et al.
Estimation of vaccination coverage from electronic healthcare records; methods performance evaluation – A contribution of the ADVANCE-project.
PloS one. 2019;14(9):e0222296. doi = 10.1371/journal.pone.0222296

Curran D, Hunjan M, El Ghachi A, El-Hahi Y, Bianco V, Ferreira G.
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
BMJ Open. 2019;9(8):e023502. doi = 10.1136/bmjopen-2018-023502

Marley C, El Hahi Y, Ferreira G, Woods L, Ramirez Villaescusa A.
Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in Clinical Practice Research Datalink.
Human vaccines & immunotherapeutics. 2019:1-7. doi = 0.1080/21645515.2019.1589288

Tin Tin Htar M, van den Biggelaar AHJ, Sings H, Ferreira G, Moffatt M, Hall-Murray C, et al.
The impact of routine childhood immunisation with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
Expert review of vaccines. 2019. doi = 10.1080/14760584.2019.1676155

Vorsters A, Bonanni P, Maltezou HC, Yarwood J, Brewer NT, Bosch FX, et al.
The role of healthcare providers in HPV vaccination programs – A meeting report.
Papillomavirus research (Amsterdam, Netherlands). 2019;8:100183. doi = 10.1016/j.pvr.2019.100183

Baay M, Bollaerts K, Verstraeten T.
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults.
Vaccine. 2018;36(29):4207-14. doi = 10.1016/j.vaccine.2018.06.004

Baay MFD, Richie TL, Neels P.
Human challenge trials in vaccine development, Rockville, MD, USA, September 28-30, 2017.
Biologicals : journal of the International Association of Biological Standardization. 2018;pii: S1045-1056(18)30039-3. . doi = 10.1016/j.biologicals.2018.02.002

Bollaerts K, De Smedt T, Donegan K, Titievsky L, Bauchau V.
Benefit-Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project.
Drug safety. 2018;41(8):775-86. doi = 10.1007/s40264-018-0658-y

Bruffaerts N, De Smedt T, Delcloo A, Simons K, Hoebeke L, Verstraeten C, et al.
Comparative long-term trend analysis of daily weather conditions with daily pollen concentrations in Brussels, Belgium.
International journal of biometeorology. 2018;62(3):483-91. doi = 10.1007/s00484-017-1457-3

Chang CH, Sakaguchi M, Weil J, Verstraeten T.
The incidence of medically-attended norovirus gastro-enteritis in Japan: Modelling using a medical care insurance claims database.
PloS one. 2018;13(3):e0195164. doi = 10.1371/journal.pone.0195164

De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K.
Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness.
PloS one. 2018;13(6):e0199180. doi = 10.1371/journal.pone.0199180

Ferreira GLC, Marano C, De Moerlooze L, Guignard A, Feng Y, El Hahi Y, et al.
Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: A population-based cohort study using the UK Clinical Practice Research Datalink.
Journal of viral hepatitis. 2018;25(5):571-81. doi = 10.1111/jvh.12841

Kowalzik F, Binder H, Zoller D, Riera-Montes M, Clemens R, Verstraeten T, et al.
Norovirus Gastroenteritis among Hospitalized Patients, Germany, 2007-2012.
Emerging infectious diseases. 2018;24(11):2021-8. doi = 10.3201/eid2411.170820

Lindsay L, DuPont HL, Moe CL, Alberer M, Hatz C, Kirby AE, et al.
Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler’s diarrhea: a prospective cohort study protocol.
BMC infectious diseases. 2018;18(1):605. doi = 10.1186/s12879-018-3461-6

McDonald SA, Nijsten D, Bollaerts K, Bauwens J, Praet N, van der Sande M, et al.
Methodology for computing the burden of disease of adverse events following immunization.
Pharmacoepidemiology and drug safety. 2018;27(7):724-30. doi = 10.1002/pds.4419

Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, et al.
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Human vaccines & immunotherapeutics. 2018;14(7):1800-6. doi = 10.1080/21645515.2018.1450125

Pircon JY, Talarico CA, Bollaerts K, Hausdorff WP, Clarke CJ.
The choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes.
Vaccine. 2018;36(46):6933-43. doi = 10.1016/j.vaccine.2018.10.003

Riera-Montes M, O’Ryan M, Verstraeten T.
Norovirus and Rotavirus disease severity in children: Systematic Review and Meta-Analysis.
The Pediatric infectious disease journal. 2018;37(6):501-5. doi = 10.1097/inf.0000000000001824

Sturkenboom M.
Advancing collaborative vaccine benefits and safety research in Europe via the ADVANCE code of conduct.
Vaccine. 2018;36(2):194-5. doi = 10.1016/j.vaccine.2017.08.043

Stuurman AL, Riera M, Lamprianou S, Perez-Vilar S, Anderson SA, Mangtani P, et al.
Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment.
Vaccine. 2018;36(45):6736-43. doi = 10.1016/j.vaccine.2018.09.033

Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, et al.
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
BMJ Open. 2018;8(6):e020528. doi = 10.1136/bmjopen-2017-020528

Baay M, Bollaerts K, Struchiner C, Verstraeten T.
Background rates of disease in Latin American children from a rotavirus vaccine study.
Human vaccines & immunotherapeutics. 2017;13(8):1916-20. doi = 10.1080/21645515.2017.1320007

Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T, et al.
A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data.
Epidemiology and infection. 2017;145(13):2666-77. doi = 10.1017/S0950268817001546

Jackson TL, Verstraeten T, Duchateau L, Lescrauwaet B.
Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
Acta ophthalmologica. 2017;95(8):e740-e5. doi = 10.1111/aos.13369

Lescrauwaet B, Duchateau L, Verstraeten T, Jackson TL. Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study. Investigative ophthalmology & visual science. 2017;58(13):5842-8. doi = 10.1167/iovs.17-22363

Lescrauwaet B, Miserocchi E, Thurau S, Bodaghi B, Duchateau L, Verstraeten T, et al.
Association Between Visual Function Response and Reduction of Inflammation in Noninfectious Uveitis of the Posterior Segment.
Investigative ophthalmology & visual science. 2017;58(9):3555-62. doi = 10.1167/iovs.17-22049

O’Ryan M, Riera-Montes M, Lopman B.
Norovirus in Latin America: Systematic Review and Meta-analysis.
The Pediatric infectious disease journal. 2017;36(2):127-34. doi = 10.1097/INF.0000000000001369

Riera-Montes M, Bollaerts K, Heininger U, Hens N, Gabutti G, Gil A, et al.
Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.
BMC infectious diseases. 2017;17(1):353. doi = 10.1186/s12879-017-2445-2

Stuurman AL, Verstraeten T, De Schryver A.
Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
Expert review of vaccines. 2017;16(2):187-91. doi = 10.1080/14760584.2017.1264272

Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et al.
Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies.
PloS one. 2017;12(5):e0177985. doi = 10.1371/journal.pone.0177985

Verstraeten T, Cattaert T, Harris J, Lopman B, Tam CC, Ferreira G.
Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets.
J Infect Dis. 2017;216(8):957-65. doi = 10.1093/infdis/jix410

Vorsters A, Arbyn M, Baay M, Bosch X, de Sanjose S, Hanley S, et al.
Overcoming barriers in HPV vaccination and screening programs.
Papillomavirus research (Amsterdam, Netherlands). 2017;4:45-53. doi = 10.1016/j.pvr.2017.07.001

Bollaerts K, Shinde V, Dos Santos G, Ferreira G, Bauchau V, Cohet C, et al.
Application of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between Pandemrix and Narcolepsy.
PloS one. 2016;11(2):e0149289. doi = 10.1371/journal.pone.0149289

Brauchli Pernus Y, Nan C, Verstraeten T, Pedenko M, Osokogu OU, Weibel D, et al.
Reference set for performance testing of pediatric vaccine safety signal detection methods and systems.
Vaccine. 2016;34(51):6626-33. doi = 10.1016/j.vaccine.2015.10.013

Marcelon L, Verstraeten T, Dominiak-Felden G, Simondon F. Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males.
Expert review of vaccines. 2016;15(1):139-48. doi = 10.1586/14760584.2016.1107480

Stassijns J, Bollaerts K, Baay M, Verstraeten T.
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children.
Vaccine. 2016;34(6):714-22. doi = 10.1016/j.vaccine.2015.12.024

Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, et al.
Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Vaccine. 2016;34(6):757-61. doi = 10.1016/j.vaccine.2015.12.063

Verstraeten T, Cohet C, Dos Santos G, Ferreira GL, Bollaerts K, Bauchau V, et al.
Pandemrix and narcolepsy: A critical appraisal of the observational studies.
Human vaccines & immunotherapeutics. 2016;12(1):187-93. doi = 10.1080/21645515.2015.1068486

Verstraeten T, Jiang B, Weil JG, Lin JH.
Modelling Estimates of Norovirus Disease in Patients with Chronic Medical Conditions.
PloS one. 2016;11(7):e0158822. doi = 10.1371/journal.pone.0158822

Willame C, Baril L, van den Bosch J, Ferreira GL, Williams R, Rosillon D, et al.
Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies.
Pharmacoepidemiology and drug safety. 2016;25(12):1397-406. doi = 10.1002/pds.4081

Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, et al.
Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study.
American journal of obstetrics and gynecology. 2012;207(3):177 e1-8. doi = 10.1016/j.ajog.2012.07.007

Van Holle L, Zeinoun Z, Bauchau V, Verstraeten T.
Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study.
Pharmacoepidemiology and drug safety. 2012;21(6):603-10. doi = 10.1002/pds.3226

Kowalzik F, Riera-Montes M, Verstraeten T, Zepp F.
The burden of norovirus disease in children in the European Union.
The Pediatric infectious disease journal. 2015;34(3):229-34. doi = 10.1097/INF.0000000000000546

Lindsay L, Wolter J, De Coster I, Van Damme P, Verstraeten T.
A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review.
BMC infectious diseases. 2015;15:425. doi = 10.1186/s12879-015-1168-5